Summary:
A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of Inclisiran Sodum given as subcutaneous inejctions in subjects with atherosclerotic cardiovascular disease (ASCVD) and elevated low density lipoprotein cholesterol (LDL-C)
Qualified Participants Must:
• Have elevated cholesterol while taking a high dose of statin (cholesterol medication) or a documented intolerance to cholesterol medications
•
Be willing to comply with study protocol for 2 years of treatment
•
History of cardiovascular disease or at risk for cardiovascular disease (contact site for details or if unsure)
Qualified Participants May Receive:
- $45 for completion of study visits
- up to $45 reimbursement for travel related expenses